{"id":"https://openalex.org/W2162777084","doi":"https://doi.org/10.1634/theoncologist.2015-0065","title":"The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab","display_name":"The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab","publication_year":2015,"publication_date":"2015-06-08","ids":{"openalex":"https://openalex.org/W2162777084","doi":"https://doi.org/10.1634/theoncologist.2015-0065","mag":"2162777084","pmid":"https://pubmed.ncbi.nlm.nih.gov/26054632"},"language":"en","primary_location":{"id":"doi:10.1634/theoncologist.2015-0065","doi":"https://doi.org/10.1634/theoncologist.2015-0065","is_oa":false,"landing_page_url":"https://doi.org/10.1634/theoncologist.2015-0065","pdf_url":null,"source":{"id":"https://openalex.org/S15523509","display_name":"The Oncologist","issn_l":"1083-7159","issn":["1083-7159","1549-490X"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316295","host_organization_name":"AlphaMed Press","host_organization_lineage":["https://openalex.org/P4310316295"],"host_organization_lineage_names":["AlphaMed Press"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Oncologist","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4492245","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5046440820","display_name":"Naifa Lamki Busaidy","orcid":"https://orcid.org/0000-0002-3808-6378","observed_orcids":["https://orcid.org/0000-0002-3808-6378"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Naifa L. Busaidy","raw_affiliation_strings":["Departments of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064953304","display_name":"Patricia Mucci LoRusso","orcid":"https://orcid.org/0000-0001-7144-036X","observed_orcids":["https://orcid.org/0000-0001-7144-036X"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]},{"id":"https://openalex.org/I4210090317","display_name":"The Barbara Ann Karmanos Cancer Institute","ror":"https://ror.org/00ee40h97","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800590384","https://openalex.org/I4210090317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patricia LoRusso","raw_affiliation_strings":["Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA;","institution_ids":["https://openalex.org/I185443292","https://openalex.org/I4210090317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021239485","display_name":"Kristie Lawhorn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristie Lawhorn","raw_affiliation_strings":["Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005194857","display_name":"Kenneth R. Hess","orcid":"https://orcid.org/0000-0003-1377-6070","observed_orcids":["https://orcid.org/0000-0003-1377-6070"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth R. Hess","raw_affiliation_strings":["Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039846489","display_name":"Mouhammed Amir Habra","orcid":"https://orcid.org/0000-0002-4148-9637","observed_orcids":["https://orcid.org/0000-0002-4148-9637"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mohammed Amir Habra","raw_affiliation_strings":["Departments of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045197829","display_name":"Siqing Fu","orcid":"https://orcid.org/0000-0002-1933-0419","observed_orcids":["https://orcid.org/0000-0002-1933-0419"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Siqing Fu","raw_affiliation_strings":["Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David S. Hong","raw_affiliation_strings":["Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110476583","display_name":"Helen X. Chen","orcid":"https://orcid.org/0000-0001-9959-8417","observed_orcids":["https://orcid.org/0000-0001-9959-8417"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Helen X. Chen","raw_affiliation_strings":["Cancer Therapy Evaluation Program, National Institutes of Health/National Cancer Institute, Rockville, Maryland, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Therapy Evaluation Program, National Institutes of Health/National Cancer Institute, Rockville, Maryland, USA;","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041531063","display_name":"L. Austin Doyle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lawrence A. Doyle","raw_affiliation_strings":["Cancer Therapy Evaluation Program, National Institutes of Health/National Cancer Institute, Rockville, Maryland, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Therapy Evaluation Program, National Institutes of Health/National Cancer Institute, Rockville, Maryland, USA;","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, California, USA","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005436649","display_name":"Aung Naing","orcid":"https://orcid.org/0000-0002-4803-8513","observed_orcids":["https://orcid.org/0000-0002-4803-8513"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Aung Naing","raw_affiliation_strings":["Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5005436649","https://openalex.org/A5046440820"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":{"value":3852,"currency":"USD","value_usd":3852},"apc_paid":null,"fwci":1.0288,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":{"value":0.75230646,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"20","issue":"7","first_page":"737","last_page":"741"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.6011000275611877,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.6011000275611877,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12465","display_name":"Cancer, Lipids, and Metabolism","score":0.0640999972820282,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11339","display_name":"Metabolism, Diabetes, and Cancer","score":0.060100000351667404,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glycemia","display_name":"glycemia","score":0.5450000166893005},{"id":"https://openalex.org/keywords/hyperlipidemia","display_name":"hyperlipidemia","score":0.9980000257492065},{"id":"https://openalex.org/keywords/temsirolimus","display_name":"temsirolimus","score":0.9449999928474426},{"id":"https://openalex.org/keywords/cixutumumab","display_name":"cixutumumab","score":0.9929999709129333},{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.8659999966621399},{"id":"https://openalex.org/keywords/combination-cancer-therapy","display_name":"combination cancer therapy","score":0.6100000143051147},{"id":"https://openalex.org/keywords/metabolic-toxicity","display_name":"metabolic toxicity","score":0.8619999885559082},{"id":"https://openalex.org/keywords/advanced-cancer","display_name":"advanced cancer","score":0.5460000038146973},{"id":"https://openalex.org/keywords/tumor-shrinkage","display_name":"tumor shrinkage","score":0.8130000233650208},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.7549999952316284},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9940000176429749},{"id":"https://openalex.org/keywords/adverse-event-management","display_name":"adverse event management","score":0.6430000066757202},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.40299999713897705},{"id":"https://openalex.org/keywords/hypertriglyceridemia","display_name":"hypertriglyceridemia","score":0.6890000104904175},{"id":"https://openalex.org/keywords/hypercholesterolemia","display_name":"hypercholesterolemia","score":0.8519999980926514}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9217289686203003},{"id":"https://openalex.org/C2776820818","wikidata":"https://www.wikidata.org/wiki/Q7699074","display_name":"Temsirolimus","level":5,"score":0.7846165299415588},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6444923877716064},{"id":"https://openalex.org/C2779091943","wikidata":"https://www.wikidata.org/wiki/Q1079120","display_name":"Hyperlipidemia","level":3,"score":0.45584553480148315},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.44784843921661377},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.35030072927474976},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3278210759162903},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.31478896737098694},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.1940239667892456},{"id":"https://openalex.org/C183713625","wikidata":"https://www.wikidata.org/wiki/Q5282002","display_name":"Discovery and development of mTOR inhibitors","level":4,"score":0.08597975969314575},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006937","descriptor_name":"Hypercholesterolemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006937","descriptor_name":"Hypercholesterolemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006937","descriptor_name":"Hypercholesterolemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006937","descriptor_name":"Hypercholesterolemia","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D006937","descriptor_name":"Hypercholesterolemia","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D006937","descriptor_name":"Hypercholesterolemia","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D006943","descriptor_name":"Hyperglycemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006943","descriptor_name":"Hyperglycemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006943","descriptor_name":"Hyperglycemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006943","descriptor_name":"Hyperglycemia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006943","descriptor_name":"Hyperglycemia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006943","descriptor_name":"Hyperglycemia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006943","descriptor_name":"Hyperglycemia","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D006943","descriptor_name":"Hyperglycemia","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D006943","descriptor_name":"Hyperglycemia","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D006949","descriptor_name":"Hyperlipidemias","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006949","descriptor_name":"Hyperlipidemias","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006949","descriptor_name":"Hyperlipidemias","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006949","descriptor_name":"Hyperlipidemias","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D006949","descriptor_name":"Hyperlipidemias","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D006949","descriptor_name":"Hyperlipidemias","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017526","descriptor_name":"Receptor, IGF Type 1","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D017526","descriptor_name":"Receptor, IGF Type 1","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D017526","descriptor_name":"Receptor, IGF Type 1","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1634/theoncologist.2015-0065","doi":"https://doi.org/10.1634/theoncologist.2015-0065","is_oa":false,"landing_page_url":"https://doi.org/10.1634/theoncologist.2015-0065","pdf_url":null,"source":{"id":"https://openalex.org/S15523509","display_name":"The Oncologist","issn_l":"1083-7159","issn":["1083-7159","1549-490X"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316295","host_organization_name":"AlphaMed Press","host_organization_lineage":["https://openalex.org/P4310316295"],"host_organization_lineage_names":["AlphaMed Press"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Oncologist","raw_type":"journal-article"},{"id":"pmid:26054632","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26054632","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The oncologist","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:pubmedcentral.nih.gov:4492245","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4492245","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Oncologist","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:4492245","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4492245","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Oncologist","raw_type":"Text"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8299999833106995,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G111615301","display_name":null,"funder_award_id":"P30 CA-016672","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G1569331433","display_name":null,"funder_award_id":"U01-CA62487","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G2521751799","display_name":null,"funder_award_id":"U01 CA 62461","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G283542464","display_name":null,"funder_award_id":"U01 CA062461","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G293200927","display_name":null,"funder_award_id":"U01 CA062487","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G553644043","display_name":null,"funder_award_id":"R21-CA13763301A1","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G6863874559","display_name":"Phase I Study of IMC-A12 in Combination with Temsirolimus","funder_award_id":"R21CA137633","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000878657","display_name":"Cancer Center Support Grant","funder_award_id":"5p30ca016672-49","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"}],"funders":[{"id":"https://openalex.org/F4320317266","display_name":"Barbara Ann Karmanos Cancer Institute","ror":"https://ror.org/00ee40h97"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320332521","display_name":"University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":12,"referenced_works":["https://openalex.org/W1991236371","https://openalex.org/W2033429522","https://openalex.org/W2059779476","https://openalex.org/W2077074120","https://openalex.org/W2104878828","https://openalex.org/W2107561358","https://openalex.org/W2129539865","https://openalex.org/W2135433020","https://openalex.org/W2136829490","https://openalex.org/W2139248078","https://openalex.org/W2168334558","https://openalex.org/W2258391373"],"related_works":["https://openalex.org/W2748952813","https://openalex.org/W1979139803","https://openalex.org/W1966504330","https://openalex.org/W2037631372","https://openalex.org/W2040058909","https://openalex.org/W2132898409","https://openalex.org/W2030889776","https://openalex.org/W1982298768","https://openalex.org/W2073895456","https://openalex.org/W2418228134"],"abstract_inverted_index":{"BACKGROUND:":[0],"Cixutumumab":[1],"(a":[2],"humanized":[3],"monoclonal":[4],"antibody":[5],"against":[6],"insulin-like":[7],"growth":[8],"factor-1":[9],"receptor":[10],"[IGF-1R])":[11],"and":[12,42,94,104,134,164,180,218,221,230,234,271,288,298,302,315,324,330,341,345],"the":[13,35,81,110,216,256,284,361],"mammalian":[14],"target":[15],"of":[16,28,37,61,143,215,228,259,279,286,306,333],"rapamycin":[17],"(mTOR)":[18],"inhibitor":[19],"temsirolimus":[20,48,229,287],"were":[21,78,169,190],"combined":[22],"in":[23,88,117,236,245],"a":[24],"phase":[25],"I":[26],"study":[27,281],"patients":[29,71,112,246,314,316,351],"with":[30,58,72,97,192,317,337],"advanced":[31],"cancer.":[32],"We":[33,84],"investigated":[34],"prevalence":[36],"metabolic":[38,86,213,238],"toxicities,":[39],"their":[40,92,95],"management,":[41,93],"impact":[43],"on":[44],"outcome.":[45],"METHODS:":[46],"The":[47,128,226,292],"dose":[49,339],"was":[50,115,138,209,232,243,264],"25":[51],"mg":[52,55],"or":[53,65,74,152,156,223,269,273,355],"37.5":[54],"i.v.":[56,68],"weekly":[57],"escalating":[59],"doses":[60],"cixutumumab":[62,231,289],"(3,":[63],"5,":[64],"6":[66],"mg/kg":[67],"weekly).":[69],"No":[70,147],"diabetes":[73],"hyperlipidemia":[75],"at":[76],"baseline":[77],"eligible":[79],"until":[80],"expansion":[82],"cohort.":[83],"assessed":[85],"derangements":[87],"our":[89],"patient":[90,148],"cohort,":[91],"association":[96,211,263],"tumor":[98,195,241],"shrinkage,":[99],"time":[100],"to":[101],"progression":[102],"(TTP)":[103],"overall":[105],"survival":[106],"(OS).":[107],"RESULTS:":[108],"Of":[109],"57":[111],"analyzed,":[113],"hyperglycemia":[114,297,354],"seen":[116,244],"36":[118],"(63%)":[119],"(grade":[120],"1-2:":[121],"33":[122],"[58%];":[123],"grade":[124],"3-4:":[125],"3":[126],"[5%]).":[127],"median":[129],"blood":[130],"sugar":[131],"level":[132],"(fasting":[133],"nonfasting)":[135],"across":[136],"cohorts":[137],"149":[139],"mg/dL":[140,171,176,182],"(upper":[141],"limit":[142],"normal:":[144],"110":[145],"mg/dL).":[146],"developed":[149,248],"diabetic":[150,313],"ketoacidosis":[151],"nonketotic":[153],"hyperosmolar":[154],"coma":[155],"pancreatitis":[157],"during":[158],"treatment.":[159],"Median":[160],"maximum":[161],"triglyceride,":[162],"cholesterol,":[163],"low-density":[165],"lipoprotein":[166],"levels":[167,189],"achieved":[168],"247":[170],"(range:":[172,177],"65-702":[173],"mg/dL),":[174,179,185],"243":[175],"103-424":[178],"153":[181],"(range":[183],"50-375":[184],"respectively.":[186],"Higher":[187],"glucose":[188],"associated":[191],"more":[193,359],"RECIST":[194],"shrinkage":[196,242],"(r":[197],"=":[198,206],"-.30":[199],"[95%":[200],"confidence":[201],"interval:":[202],"-.52,":[203],"-.03;":[204],"p":[205],".03]).":[207],"There":[208],"no":[210,261],"between":[212,266,322],"toxicities":[214],"mTOR":[217],"IGF-1R":[219],"combination":[220,227,285,305],"TTP":[222,272],"OS.":[224,274],"CONCLUSION:":[225],"safe":[233],"resulted":[235],"manageable":[237],"toxicities.":[239],"More":[240],"who":[247,352],"these":[249,334],"adverse":[250,335],"events.":[251],"Although":[252],"perhaps":[253],"limited":[254],"by":[255],"small":[257],"number":[258],"patients,":[260],"significant":[262],"discerned":[265],"hyperglycemia,":[267],"hypertriglyceridemia,":[268],"hypercholesterolemia":[270,356],"IMPLICATIONS":[275],"FOR":[276],"PRACTICE:":[277],"Results":[278],"this":[280],"show":[282],"that":[283],"is":[290,348],"safe.":[291],"most":[293],"common":[294],"side":[295],"effects,":[296],"hyperlipidemia,":[299],"are":[300],"tolerable":[301],"manageable.":[303],"This":[304],"therapies":[307],"should":[308],"not":[309],"be":[310],"withheld":[311],"from":[312,360],"high":[318],"cholesterol":[319],"levels.":[320],"Collaboration":[321],"oncologist":[323],"endocrinologist":[325],"allows":[326],"for":[327],"individualized":[328],"treatment":[329],"better":[331],"control":[332],"events,":[336],"few":[338],"interruptions":[340],"reductions.":[342],"Supportive":[343],"care":[344],"close":[346],"monitoring":[347],"needed.":[349],"Those":[350],"develop":[353],"may":[357],"benefit":[358],"drug.":[362]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":4},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2025-10-10T00:00:00"}